EAM (ETOPOSIDE, CYTARABINE, MELPHALAN) BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR RESISTANT/RELAPSED HODGKIN LYMPHOMA PATIENTS.
(Abstract release date: 05/21/15)
EHA Library. Amine Bekadja M. 06/12/15; 102664; PB2028
Disclosure(s): University hospital OranHematology and cell therapy
Mohamed Amine Bekadja
Contributions
Contributions
Abstract
Abstract: PB2028
Type: Publication Only
Background
High-dose chemotherapy (HDT) followed by autologous stem cell rescue has become the standard of care for patients with relapsed, chemo- sensitive Hodgkin lymphoma (HL). A BEAM regimen is widely used conditioning regimen for autologous stem cells transplant (ASCT) in patients with lymphoma because of its acceptable toxicity and high effectiveness. Adverse events associated with BEAM are related in part to BICNU.
Aims
On 2011-2012, we started a pilot study designed as follows: Etoposide 800 mg/m2 J-5 to J-2, Cytarabine 1000 mg/m2/12h, J-5 to J-2 and Melphalan 140 mg/m2 J-1 as the conditioning regimen to ASCT for resistant/relapsed HL patientsto evaluate the safety and the efficacy of this regimen with high dose Cytarabine.
Methods
Seventeen patients, seven males and ten females, 17 to 51 years old (median, 28 years), with HL were consecutively treated in our center. Regarding the stage of disease, four patients were in early stage (I-II), thirteen in advanced stage (III-IV) and concerning their status at ASCT, thirteen were in complete remission, three in partial response and one presented a refractory disease. A median number of 3,73x106 CD34+ cells/kg (range, 2, 97-6, 15) were re-infused.
Results
All patients had a full hematopoietic reconstitution. Median time to achieve neutrophils >500 /μl was 13 days (range: 9-19) and median time to achieve an unsupported platelet count >20,000/μl was16 days (range: 14-25). Toxicities included grade 4 hematologic in all patients, grade 3 mucositis in 4, grade 3 infectious in 2. Among 16 patients evaluable, fifteen patients (94%) achieved CR; one patient had progressive disease post-ASCT.Fivepatients died: one within the first 100 days that followed transplantation, one after progression of disease and three after relapse. After a median follow up of 37 months (2-45) (End point: 31/12/2014), the overall survival was 70% at 45 months, the DFS was 75% at 45 months and 12 patients are alive in continuous CR (80%).
Summary
In conclusion, this pilot studyof EAMas conditioning regimen seems to be safeand effective for heavily pre-treated Hodgkin lymphoma patients. Although these outcomes are encouraging, our results need to be confirmed by more other studies.
Keyword(s): Autologous peripheral blood stem cell tansplantati, Hodgkin's lymphoma
Session topic: Publication Only
Type: Publication Only
Background
High-dose chemotherapy (HDT) followed by autologous stem cell rescue has become the standard of care for patients with relapsed, chemo- sensitive Hodgkin lymphoma (HL). A BEAM regimen is widely used conditioning regimen for autologous stem cells transplant (ASCT) in patients with lymphoma because of its acceptable toxicity and high effectiveness. Adverse events associated with BEAM are related in part to BICNU.
Aims
On 2011-2012, we started a pilot study designed as follows: Etoposide 800 mg/m2 J-5 to J-2, Cytarabine 1000 mg/m2/12h, J-5 to J-2 and Melphalan 140 mg/m2 J-1 as the conditioning regimen to ASCT for resistant/relapsed HL patientsto evaluate the safety and the efficacy of this regimen with high dose Cytarabine.
Methods
Seventeen patients, seven males and ten females, 17 to 51 years old (median, 28 years), with HL were consecutively treated in our center. Regarding the stage of disease, four patients were in early stage (I-II), thirteen in advanced stage (III-IV) and concerning their status at ASCT, thirteen were in complete remission, three in partial response and one presented a refractory disease. A median number of 3,73x106 CD34+ cells/kg (range, 2, 97-6, 15) were re-infused.
Results
All patients had a full hematopoietic reconstitution. Median time to achieve neutrophils >500 /μl was 13 days (range: 9-19) and median time to achieve an unsupported platelet count >20,000/μl was16 days (range: 14-25). Toxicities included grade 4 hematologic in all patients, grade 3 mucositis in 4, grade 3 infectious in 2. Among 16 patients evaluable, fifteen patients (94%) achieved CR; one patient had progressive disease post-ASCT.Fivepatients died: one within the first 100 days that followed transplantation, one after progression of disease and three after relapse. After a median follow up of 37 months (2-45) (End point: 31/12/2014), the overall survival was 70% at 45 months, the DFS was 75% at 45 months and 12 patients are alive in continuous CR (80%).
Summary
In conclusion, this pilot studyof EAMas conditioning regimen seems to be safeand effective for heavily pre-treated Hodgkin lymphoma patients. Although these outcomes are encouraging, our results need to be confirmed by more other studies.
Keyword(s): Autologous peripheral blood stem cell tansplantati, Hodgkin's lymphoma
Session topic: Publication Only
Abstract: PB2028
Type: Publication Only
Background
High-dose chemotherapy (HDT) followed by autologous stem cell rescue has become the standard of care for patients with relapsed, chemo- sensitive Hodgkin lymphoma (HL). A BEAM regimen is widely used conditioning regimen for autologous stem cells transplant (ASCT) in patients with lymphoma because of its acceptable toxicity and high effectiveness. Adverse events associated with BEAM are related in part to BICNU.
Aims
On 2011-2012, we started a pilot study designed as follows: Etoposide 800 mg/m2 J-5 to J-2, Cytarabine 1000 mg/m2/12h, J-5 to J-2 and Melphalan 140 mg/m2 J-1 as the conditioning regimen to ASCT for resistant/relapsed HL patientsto evaluate the safety and the efficacy of this regimen with high dose Cytarabine.
Methods
Seventeen patients, seven males and ten females, 17 to 51 years old (median, 28 years), with HL were consecutively treated in our center. Regarding the stage of disease, four patients were in early stage (I-II), thirteen in advanced stage (III-IV) and concerning their status at ASCT, thirteen were in complete remission, three in partial response and one presented a refractory disease. A median number of 3,73x106 CD34+ cells/kg (range, 2, 97-6, 15) were re-infused.
Results
All patients had a full hematopoietic reconstitution. Median time to achieve neutrophils >500 /μl was 13 days (range: 9-19) and median time to achieve an unsupported platelet count >20,000/μl was16 days (range: 14-25). Toxicities included grade 4 hematologic in all patients, grade 3 mucositis in 4, grade 3 infectious in 2. Among 16 patients evaluable, fifteen patients (94%) achieved CR; one patient had progressive disease post-ASCT.Fivepatients died: one within the first 100 days that followed transplantation, one after progression of disease and three after relapse. After a median follow up of 37 months (2-45) (End point: 31/12/2014), the overall survival was 70% at 45 months, the DFS was 75% at 45 months and 12 patients are alive in continuous CR (80%).
Summary
In conclusion, this pilot studyof EAMas conditioning regimen seems to be safeand effective for heavily pre-treated Hodgkin lymphoma patients. Although these outcomes are encouraging, our results need to be confirmed by more other studies.
Keyword(s): Autologous peripheral blood stem cell tansplantati, Hodgkin's lymphoma
Session topic: Publication Only
Type: Publication Only
Background
High-dose chemotherapy (HDT) followed by autologous stem cell rescue has become the standard of care for patients with relapsed, chemo- sensitive Hodgkin lymphoma (HL). A BEAM regimen is widely used conditioning regimen for autologous stem cells transplant (ASCT) in patients with lymphoma because of its acceptable toxicity and high effectiveness. Adverse events associated with BEAM are related in part to BICNU.
Aims
On 2011-2012, we started a pilot study designed as follows: Etoposide 800 mg/m2 J-5 to J-2, Cytarabine 1000 mg/m2/12h, J-5 to J-2 and Melphalan 140 mg/m2 J-1 as the conditioning regimen to ASCT for resistant/relapsed HL patientsto evaluate the safety and the efficacy of this regimen with high dose Cytarabine.
Methods
Seventeen patients, seven males and ten females, 17 to 51 years old (median, 28 years), with HL were consecutively treated in our center. Regarding the stage of disease, four patients were in early stage (I-II), thirteen in advanced stage (III-IV) and concerning their status at ASCT, thirteen were in complete remission, three in partial response and one presented a refractory disease. A median number of 3,73x106 CD34+ cells/kg (range, 2, 97-6, 15) were re-infused.
Results
All patients had a full hematopoietic reconstitution. Median time to achieve neutrophils >500 /μl was 13 days (range: 9-19) and median time to achieve an unsupported platelet count >20,000/μl was16 days (range: 14-25). Toxicities included grade 4 hematologic in all patients, grade 3 mucositis in 4, grade 3 infectious in 2. Among 16 patients evaluable, fifteen patients (94%) achieved CR; one patient had progressive disease post-ASCT.Fivepatients died: one within the first 100 days that followed transplantation, one after progression of disease and three after relapse. After a median follow up of 37 months (2-45) (End point: 31/12/2014), the overall survival was 70% at 45 months, the DFS was 75% at 45 months and 12 patients are alive in continuous CR (80%).
Summary
In conclusion, this pilot studyof EAMas conditioning regimen seems to be safeand effective for heavily pre-treated Hodgkin lymphoma patients. Although these outcomes are encouraging, our results need to be confirmed by more other studies.
Keyword(s): Autologous peripheral blood stem cell tansplantati, Hodgkin's lymphoma
Session topic: Publication Only
{{ help_message }}
{{filter}}